Browsing eNauka
Browsing by Author Hanes, Vladimir
Showing results 1 to 5 of 5
| Issue Date | Title | Author(s) | Type | М-cat. |
|---|---|---|---|---|
| 2018 | Abstract PD3-10: Safety results from a randomized, double-blind, phase 3 study of ABP 980 compared with trastuzumab in patients with breast cancer (✓) | Kolberg, Hans-Christian; Demetriou, Georgia S; Zhang, Nan; Tomasevic, Zorica I   ; Hanes, Vladimir | Conference Paper | Mp. category will be shown later |
| 2020 | Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study (✓) | Kolberg, Hans-Christian; Colleoni, Marco A; Sawa-Demetriou, G; Santi, Patricia Xavier; Tesch, Hans; Fujiwara, Yasuhiro; Tomasevic, Zorica I ; Hanes, Vladimir | Article | 21aM21a |
| 2018 | Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications | Kolberg, Hans-Christian; Tomasevic, Zoran M; Demetriou, Georgia S; von, Minckwitz Gunter; Fujiwara, Yasuhiro; Ponomarova, O; Tesch, Hans; Santi, Patricia Xavier; Hanes, Vladimir | Conference Paper | Mp. category will be shown later |
| 2018 | Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial (✓) | von, Minckwitz Gunter; Colleoni, Marco A; Kolberg, Hans-Christian; Morales, Serafin; Santi, Patricia Xavier; Tomasevic, Zorica I ; Zhang, Nan; Hanes, Vladimir | Article | 21aM21a |
| 2019 | Matching the critical function of the biosimilar ABP 980 and trastuzumab: Totality of evidence and scientific justification for extrapolation across trastuzumab indications | Kolberg, Hans-Christian; Colleoni, Marco A; Tomasevic, Zoran M; Ponomarova, O; McBride, HJ; Tesch, Hans; Hanes, Vladimir | Conference Paper | Mp. category will be shown later |